Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Reduces Brain Damage after Stroke in the Neonatal Mouse Brain

Philippe Bonnin1, Tania Vitalis2, Leslie Schwendimann2

  • 1U1148, LVTS, INSERM, F-75018, Physiologie Clinique-Explorations Fonctionnelles, Hôpital Lariboisiere, Université de Paris, 75010 Paris, France.

Insights

The poly(ADP-ribose) polymerase inhibitor PJ34 improved blood flow and reduced brain damage after neonatal stroke in mice. PJ34 protected the blood-brain barrier and decreased astrocyte death, particularly in rostral brain areas.

Area of Science:

  • Neuroscience
  • Cerebrovascular Research
  • Pharmacology

Background:

  • Neonatal ischemia can cause significant long-term neurological deficits.
  • The poly(ADP-ribose) polymerase inhibitor PJ34 has shown potential in enhancing cerebral blood flow.
  • Understanding the effects of PJ34 on the neurovascular unit after neonatal stroke is crucial.

Purpose of the Study:

  • To investigate the therapeutic benefits of PJ34 in a neonatal mouse model of ischemic stroke.
  • To assess the impact of PJ34 on cerebral hemodynamics, blood-brain barrier integrity, and glial cell responses.

Main Methods:

  • Neonatal mice underwent permanent middle cerebral artery occlusion (pMCAo) and received either PJ34 or PBS treatment.
  • Cerebral blood flow was measured using Doppler-ultrasonography.
  • Blood-brain barrier opening, astrocyte survival, and lesion volume were evaluated at various time points post-ischemia.

Main Results:

  • PJ34 administration prevented the drop in cerebral blood flow in the ipsilesional internal carotid artery (ICA) and increased flow in the contralesional ICA.
  • PJ34 treatment reduced blood-brain barrier disruption and astrocyte demise in the rostral brain regions.
  • While PJ34 reduced lesion areas in specific rostral territories, overall total tissue loss was not significantly altered.

Conclusions:

  • PJ34 demonstrates neuroprotective effects following neonatal ischemic stroke by improving hemodynamics and preserving the blood-brain barrier.
  • The drug's benefits appear localized to rostral brain areas, suggesting a role for anterior ICA collateral supply.
  • Further research is warranted to explore PJ34's full therapeutic potential in neonatal stroke.

Related Concept Videos